Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

High-throughput mapping of CoA metabolites by SAMDI-MS to optimize the cell-free biosynthesis of HMG-CoA.

O'Kane PT, Dudley QM, McMillan AK, Jewett MC, Mrksich M.

Sci Adv. 2019 Jun 5;5(6):eaaw9180. doi: 10.1126/sciadv.aaw9180. eCollection 2019 Jun.

2.

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP.

Br J Haematol. 2019 Mar;184(6):957-968. doi: 10.1111/bjh.15722. Epub 2018 Dec 13.

PMID:
30548597
3.

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.

Patel B, Kirkwood AA, Dey A, Marks DI, McMillan AK, Menne TF, Micklewright L, Patrick P, Purnell S, Rowntree CJ, Smith P, Fielding AK.

Leukemia. 2017 Jan;31(1):58-64. doi: 10.1038/leu.2016.219. Epub 2016 Aug 2.

4.

Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.

Bishton MJ, McMillan AK, Fox CP.

Br J Haematol. 2017 Apr;177(2):320-321. doi: 10.1111/bjh.14050. Epub 2016 Mar 28. No abstract available.

PMID:
27018322
5.

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP.

Br J Haematol. 2016 Jan;172(2):246-54. doi: 10.1111/bjh.13831. Epub 2015 Nov 18.

PMID:
26577576
6.

Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort.

Bishton MJ, Hubbard R, Witherall R, Jones SG, Richardson F, James EJ, Sovani V, Bessell EM, Haynes AP, McMillan AK, Fox CP.

Ann Oncol. 2015 Nov;26(11):2356-7. doi: 10.1093/annonc/mdv359. Epub 2015 Sep 15. No abstract available.

PMID:
26374286
7.

Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings.

Sovani V, Harvey C, Haynes AP, McMillan AK, Clark DM, O'Connor SR.

J Clin Pathol. 2014 May;67(5):389-95. doi: 10.1136/jclinpath-2013-201520. Epub 2013 Dec 10.

PMID:
24327662
8.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH.

Blood. 2014 Feb 6;123(6):843-50. doi: 10.1182/blood-2013-09-529008. Epub 2013 Nov 25.

9.

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial.

Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison CJ, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM.

Haematologica. 2013 Jun;98(6):945-52. doi: 10.3324/haematol.2012.081877. Epub 2013 Jan 24.

10.

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM.

Blood. 2009 Dec 10;114(25):5136-45. doi: 10.1182/blood-2009-08-231217.

11.

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.

Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH.

Blood. 2009 May 7;113(19):4489-96. doi: 10.1182/blood-2009-01-199380. Epub 2009 Feb 24.

12.

IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.

Fox CP, McMillan AK, Bishton MJ, Haynes AP, Russell NH.

Br J Haematol. 2008 Apr;141(2):244-8. doi: 10.1111/j.1365-2141.2008.07068.x.

PMID:
18353164
13.

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.

Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH; Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group.

Blood. 2007 Feb 1;109(3):944-50. Epub 2006 Oct 10.

14.

Detection and significance of bone marrow infiltration at the time of autologous bone marrow transplantation in Hodgkin's disease.

Chopra R, Wotherspoon AC, Blair S, McMillan AK, Mills W, Fielding AK, Linch DC, Goldstone AH.

Br J Haematol. 1994 Jul;87(3):647-9.

PMID:
7993812
15.

Successful pregnancies in women following single autotransplant for acute myeloid leukemia with a chemotherapy ablation protocol.

Salooja N, Chatterjee R, McMillan AK, Kelsey SM, Newland AC, Milligan DW, Franklin IM, Hutchinson RM, Linch DC, Goldstone AH.

Bone Marrow Transplant. 1994 Apr;13(4):431-5.

PMID:
8019467
16.

The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.

Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH.

Blood. 1993 Mar 1;81(5):1137-45.

17.
18.

Conceptual problems in relation to dose escalation in the first remission of Hodgkin's disease.

Goldstone AH, McMillan AK.

Ann Oncol. 1992 Sep;3 Suppl 4:91-3.

PMID:
1450087
19.

The effect of macrophage colony-stimulating factor on haemopoietic recovery after autologous bone marrow transplantation.

Khwaja A, Yong K, Jones HM, Chopra R, McMillan AK, Goldstone AH, Patterson KG, Matheson C, Ruthven K, Abramson SB, et al.

Br J Haematol. 1992 Jun;81(2):288-95.

PMID:
1643027
20.

Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.

Chopra R, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D, Richards JD, Cervi P, Kinsey S, Goldstone AH.

Br J Haematol. 1992 Jun;81(2):197-202.

PMID:
1643017
21.

Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience.

Chopra R, Goldstone AH, McMillan AK, Powles R, Smith AG, Prentice HG, Reid C, Marcus R, Bell A, Milligan D, et al.

J Clin Oncol. 1991 Oct;9(10):1840-7.

PMID:
1919634
22.

Autologous bone marrow transplantation for non-Hodgkin's lymphoma.

McMillan AK, Goldstone AH.

Eur J Haematol. 1991 Mar;46(3):129-35. Review.

PMID:
2009945
23.

A unique case of three autografts for acute myelogenous leukaemia with subsequent long term survival in second remission.

Lim SH, McMillan AK, Gribben J, Galvin MC, Goldstone AH.

Leuk Lymphoma. 1991;5(2-3):207-9. doi: 10.3109/10428199109068127.

PMID:
21269083
24.

Transplant related septicaemia in patients undergoing autologous bone marrow transplantation for lymphoma and acute leukaemia.

Lim SH, McMillan AK, Chopra R, Kinsey SE, Cervi P, Salooja N, Smith MP, Holton J, Linch DC, Goldstone AH.

Leuk Lymphoma. 1991;5(2-3):127-32. doi: 10.3109/10428199109068115.

PMID:
21269071
25.

High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia.

McMillan AK, Goldstone AH, Linch DC, Gribben JG, Patterson KG, Richards JD, Franklin I, Boughton BJ, Milligan DW, Leyland MM, et al.

Blood. 1990 Aug 1;76(3):480-8.

26.

A comparison of the outcome of ABMT in first remission acute myeloid and lymphoblastic leukemia in a single centre.

McMillan AK, Goldstone AH, Chopra R, Linch DC.

Bone Marrow Transplant. 1990 Jul;6 Suppl 1:72. No abstract available.

PMID:
2202472
27.

Autologous Bone-Marrow Transplantation in Acute Lymphoblastic Leukaemia: 1980-89.

Mcmillan AK, Gribben JG, Linch DC, Anderson C, Richards JD, Goldstone AH.

Leuk Lymphoma. 1990;1(3-4):157-62. doi: 10.3109/10428199009042474.

PMID:
27463980
28.

Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy.

Gribben JG, Goldstone AH, Linch DC, Taghipour G, McMillan AK, Souhami RL, Earl H, Richards JD.

J Clin Oncol. 1989 Nov;7(11):1621-9.

PMID:
2809678
29.

Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation.

Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH.

Blood. 1989 Jan;73(1):340-4.

Supplemental Content

Loading ...
Support Center